
KRTX
Healthcare · Biotechnology · $12.60B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · -12.5% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 22, 2024 | Before the open | -2.65 | -3.01 | -13.6% |
| Nov 2, 2023 | Before the open | -2.74 | -3.16 | -15.3% |
| Aug 3, 2023 | Before the open | -2.78 | -2.75 | +1.1% |
| May 4, 2023 | Before the open | -2.76 | -2.80 | -1.4% |
| Feb 23, 2023 | Before the open | -2.25 | -2.22 | +1.3% |
| Nov 3, 2022 | Before the open | -2.13 | -2.38 | -11.7% |
| Aug 8, 2022 | Before the open | -2.09 | -2.17 | -3.8% |
| May 5, 2022 | Before the open | -2.11 | -1.95 | +7.6% |
| Feb 24, 2022 | Before the open | -1.73 | -0.94 | +45.7% |
| Nov 4, 2021 | Before the open | -1.44 | -1.72 | -19.4% |
| Aug 5, 2021 | Before the open | -1.34 | -1.17 | +12.7% |
| May 6, 2021 | Before the open | -1.13 | -1.07 | +5.3% |
| Feb 25, 2021 | Before the open | -0.90 | -0.89 |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and…
| +1.1% |
| Nov 5, 2020 | Before the open | -0.82 | -0.71 | +13.4% |
| Aug 5, 2020 | Before the open | -0.45 | -0.65 | -44.4% |
| May 7, 2020 | Before the open | -0.41 | -0.33 | +19.5% |
| Mar 24, 2020 | Before the open | -0.47 | -0.32 | +31.9% |
| Nov 7, 2019 | Before the open | -0.45 | -0.39 | +13.3% |
| Aug 8, 2019 | Before the open | -0.87 | -0.65 | +25.3% |
| Jun 28, 2019 | After the close | 0.00 | -1.10 | — |